Cytokinetics, Incorporated
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CYTK | EWTX | SLDB | SRRK | BBIO | BMRN | |
|---|---|---|---|---|---|---|
| Market cap | 8.73B | 4.18B | 719.48M | 5.11B | 12.85B | 10.72B |
| P/E (TTM) | — | — | — | — | — | 149.7 |
| Forward P/E | -14.1 | -21.2 | -3.9 | -16.6 | 2,275.1 | 8.3 |
| Price/book | -50.2 | 9.2 | 1.9 | 20.1 | -5.1 | 1.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +2.88% | +165.53% | +14.31% | +23.09% | +16.37% | +5.57% |
| Today | −0.19% | −1.56% | −2.33% | −0.59% | +0.61% | +1.09% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CYTK news ›Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Intel Accelerates Open Infrastructure for the Agentic AI Era The additional analyses showed broader clinical responses versus placebo, alongside higher rates of serious heart failure events. At 36 weeks, aficamten improved a composite…
Head to Head Comparison: Cytokinetics (NASDAQ:CYTK) vs. Pluri (NASDAQ:PLUR)
Posted by Danessa Lincoln on Oct 10th, 2026 Pluri (NASDAQ:PLUR – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses…
Analyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK)
Cytokinetics (NASDAQ:CYTK – Get Free Report) and Zai Lab (NASDAQ:ZLAB – Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their…
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations,…
Cytokinetics Announces Four Presentations at HFSA 2026 Highlighting Aficamten Data in Hypertrophic Cardiomyopathy | CYTK Stock News
Cytokinetics will present at the HFSA Annual Scientific Meeting 2026 from October 9–12, 2026. Presenters include Dr. Martin Maron, Dr. Gregory Lewis, Dr. Yasuhiro Hamatani, and Dr. Ahmad Masri. Topics include the efficacy of aficamten in…
Cytokinetics (CYTK) Launches ASPEN-HCM Study to Evaluate Myqorzo
The GF Score™ aggregates multiple fundamental factors to provide a snapshot of a company’s overall financial health, profitability, growth potential, valuation attractiveness, and market momentum. Cytokinetics’ GF Score™ of 57/100 reflects…
Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
TradingView Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Announces Start of ASPEN-HCM Real-World Study of MYQORZO in Symptomatic Obstructive HCM | CYTK Stock News
The ASPEN-HCM study aims to evaluate the safety, effectiveness, and economic impact of MYQORZO in patients with symptomatic obstructive HCM. The study is led by the University of California, San Francisco (UCSF) in collaboration with…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
quiverquant.com2
-
defenseworld.net1
-
gurufocus.com1
-
themarketsdaily.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.